Comparative Pharmacology
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus OLOPATADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus OLOPATADINE HYDROCHLORIDE.
CYPROHEPTADINE HYDROCHLORIDE vs OLOPATADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a potent antihistamine (H1 receptor antagonist) and antiserotonergic agent (5-HT2 receptor antagonist). It also exhibits weak anticholinergic and sedative properties. It blocks histamine-mediated vasodilation, increased capillary permeability, and pruritus, as well as serotonin-mediated effects on appetite and mood.
Olopatadine hydrochloride is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits histamine release from mast cells and prevents histamine-induced effects such as increased vascular permeability and pruritus.
4 mg orally three times daily; range 4-20 mg/day, not to exceed 0.5 mg/kg/day
One drop of 0.1% or 0.2% ophthalmic solution in each affected eye twice daily (every 6-8 hours) for 0.1%; once daily for 0.2%.
None Documented
None Documented
Terminal half-life approximately 8–16 hours in adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life of 8–12 hours in healthy adults; prolonged in hepatic impairment (up to 18 hours)
Primarily renal (appreciable unchanged drug and metabolites); biliary/fecal elimination minor (<5%).
Primarily renal excretion (60-70% unchanged), with minor biliary/fecal elimination (~30% as metabolites)
Category A/B
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer